| Analysis | Metabolite Name | Measured Value | Units | Genotype | Treatment | Metabolite | Tissue |
|---|---|---|---|---|---|---|---|
| None (Direct infusion) NEGATIVE ION MODE | RvD4 | 0.124 | ng/mL | F344 Pirc | LD TP-252 (1.5% EPA) | Eicosanoid | Plasma |
| None (Direct infusion) NEGATIVE ION MODE | RvD4 | 0.130 | ng/mL | F344 Pirc | EPA-FFA (2% EPA) | Eicosanoid | Plasma |
| None (Direct infusion) NEGATIVE ION MODE | RvD4 | 0.145 | ng/mL | F344 Pirc | HD TP-252 (3% EPA) + 200 ppm Naproxen | Eicosanoid | Plasma |
| None (Direct infusion) NEGATIVE ION MODE | RvD4 | 0.229 | ng/mL | F344 Pirc | EPA-FFA (2% EPA) | Eicosanoid | Plasma |
| None (Direct infusion) NEGATIVE ION MODE | RvD4 | 0.247 | ng/mL | F344 Pirc | LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Eicosanoid | Plasma |
| None (Direct infusion) NEGATIVE ION MODE | RvD4 | 0.273 | ng/mL | F344 Pirc | EPA-FFA (2%) + 200 ppm Naproxen | Eicosanoid | Plasma |
| None (Direct infusion) NEGATIVE ION MODE | RvD4 | 0.274 | ng/mL | F344 Pirc | LD TP-252 (1.5% EPA) | Eicosanoid | Plasma |
| None (Direct infusion) NEGATIVE ION MODE | RvD4 | 0.282 | ng/mL | F344 Pirc | EPA-FFA (2%) + 200 ppm Naproxen | Eicosanoid | Plasma |
| None (Direct infusion) NEGATIVE ION MODE | RvD4 | 0.325 | ng/mL | F344 Pirc | 200 ppm Naproxen | Eicosanoid | Plasma |
| None (Direct infusion) NEGATIVE ION MODE | RvD4 | 0.335 | ng/mL | F344 Pirc | EPA-FFA (2%) + 200 ppm Naproxen | Eicosanoid | Plasma |
| None (Direct infusion) NEGATIVE ION MODE | RvD4 | 0.342 | ng/mL | F344 Pirc | LD TP-252 (1.5% EPA) | Eicosanoid | Plasma |
| None (Direct infusion) NEGATIVE ION MODE | RvD4 | 0.357 | ng/mL | F344 Pirc | HD TP-252 (3% EPA) + 200 ppm Naproxen | Eicosanoid | Plasma |
| None (Direct infusion) NEGATIVE ION MODE | RvD4 | 0.366 | ng/mL | F344 Pirc | AIN-93G (control) | Eicosanoid | Plasma |
| None (Direct infusion) NEGATIVE ION MODE | RvD4 | 0.372 | ng/mL | F344 Pirc | LD TP-252 (1.5% EPA) | Eicosanoid | Plasma |
| None (Direct infusion) NEGATIVE ION MODE | RvD4 | 0.384 | ng/mL | F344 Pirc | EPA-FFA (2% EPA) | Eicosanoid | Plasma |
| None (Direct infusion) NEGATIVE ION MODE | RvD4 | 0.437 | ng/mL | F344 Pirc | EPA-FFA (2%) + 200 ppm Naproxen | Eicosanoid | Plasma |
| None (Direct infusion) NEGATIVE ION MODE | RvD4 | 0.441 | ng/mL | F344 Pirc | HD TP-252 (3% EPA) + 200 ppm Naproxen | Eicosanoid | Plasma |
| None (Direct infusion) NEGATIVE ION MODE | RvD4 | 0.446 | ng/mL | F344 Pirc | HD TP-252 (3% EPA) | Eicosanoid | Plasma |
| None (Direct infusion) NEGATIVE ION MODE | RvD4 | 0.458 | ng/mL | F344 Pirc | EPA-FFA (2% EPA) | Eicosanoid | Plasma |
| None (Direct infusion) NEGATIVE ION MODE | RvD4 | 0.533 | ng/g tissue | F344 Pirc | AIN-93G (control) | Eicosanoid | Tumor-adjacent normal colon |
| None (Direct infusion) NEGATIVE ION MODE | RvD4 | 0.550 | ng/g tissue | F344 Pirc | EPA-FFA (2%) + 200 ppm Naproxen | Eicosanoid | Tumor-adjacent normal colon |
| None (Direct infusion) NEGATIVE ION MODE | RvD4 | ng/g tissue | F344 Pirc | 200 ppm Naproxen | Eicosanoid | Tumor-adjacent normal colon | |
| None (Direct infusion) NEGATIVE ION MODE | RvD4 | ng/g tissue | F344 Pirc | AIN-93G (control) | Eicosanoid | Tumor-adjacent normal colon | |
| None (Direct infusion) NEGATIVE ION MODE | RvD4 | ng/g tissue | F344 Pirc | EPA-FFA (2%) + 200 ppm Naproxen | Eicosanoid | Tumor-adjacent normal colon | |
| None (Direct infusion) NEGATIVE ION MODE | RvD4 | ng/g tissue | F344 Pirc | EPA-FFA (2% EPA) | Eicosanoid | Tumor-adjacent normal colon | |
| None (Direct infusion) NEGATIVE ION MODE | RvD4 | ng/g tissue | F344 Pirc | HD TP-252 (3% EPA) + 200 ppm Naproxen | Eicosanoid | Tumor-adjacent normal colon | |
| None (Direct infusion) NEGATIVE ION MODE | RvD4 | ng/g tissue | F344 Pirc | HD TP-252 (3% EPA) | Eicosanoid | Tumor-adjacent normal colon | |
| None (Direct infusion) NEGATIVE ION MODE | RvD4 | ng/g tissue | F344 Pirc | LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Eicosanoid | Tumor-adjacent normal colon | |
| None (Direct infusion) NEGATIVE ION MODE | RvD4 | ng/g tissue | F344 Pirc | LD TP-252 (1.5% EPA) | Eicosanoid | Tumor-adjacent normal colon | |
| None (Direct infusion) NEGATIVE ION MODE | RvD4 | ng/mL | F344 Pirc | 200 ppm Naproxen | Eicosanoid | Plasma | |
| None (Direct infusion) NEGATIVE ION MODE | RvD4 | ng/mL | F344 Pirc | AIN-93G (control) | Eicosanoid | Plasma | |
| None (Direct infusion) NEGATIVE ION MODE | RvD4 | ng/mL | F344 Pirc | EPA-FFA (2%) + 200 ppm Naproxen | Eicosanoid | Plasma | |
| None (Direct infusion) NEGATIVE ION MODE | RvD4 | ng/mL | F344 Pirc | EPA-FFA (2% EPA) | Eicosanoid | Plasma | |
| None (Direct infusion) NEGATIVE ION MODE | RvD4 | ng/mL | F344 Pirc | HD TP-252 (3% EPA) + 200 ppm Naproxen | Eicosanoid | Plasma | |
| None (Direct infusion) NEGATIVE ION MODE | RvD4 | ng/mL | F344 Pirc | HD TP-252 (3% EPA) | Eicosanoid | Plasma | |
| None (Direct infusion) NEGATIVE ION MODE | RvD4 | ng/mL | F344 Pirc | LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Eicosanoid | Plasma | |
| None (Direct infusion) NEGATIVE ION MODE | RvD4 | ng/mL | F344 Pirc | LD TP-252 (1.5% EPA) | Eicosanoid | Plasma |
- UCSD Metabolomics Workbench, a resource sponsored by the Common Fund of the National Institutes of Health
|